home / stock / omed / omed quote
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.89 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $0.89 | $N/A | $N/A | 0 | 04-30-2019 |
$ | $N/A | $0.89 | $N/A | $N/A | 0 | 04-29-2019 |
$ | $N/A | $0.89 | $N/A | $N/A | 0 | 04-26-2019 |
$ | $N/A | $0.89 | $N/A | $N/A | 0 | 04-25-2019 |
$ | $N/A | $0.89 | $N/A | $N/A | 0 | 04-24-2019 |
$ | $N/A | $0.89 | $N/A | $N/A | 1,201 | 04-23-2019 |
$ | $0.9361 | $0.89 | $0.9361 | $0.85 | 479,903 | 04-22-2019 |
$ | $1.05 | $0.9399 | $1.05 | $0.92 | 1,982,202 | 04-19-2019 |
$ | $1.05 | $0.9399 | $1.05 | $0.92 | 1,982,202 | 04-18-2019 |
$ | $1.03 | $1.07 | $1.27 | $0.82 | 6,046,124 | 04-17-2019 |
$ | $1.06 | $1.02 | $1.07 | $0.9529 | 930,529 | 04-16-2019 |
$ | $0.9496 | $0.99 | $0.995 | $0.90 | 1,283,753 | 04-15-2019 |
$ | $0.9788 | $0.9164 | $0.9949 | $0.885 | 260,375 | 04-12-2019 |
$ | $0.9479 | $0.96 | $0.9998 | $0.932 | 75,472 | 04-11-2019 |
$ | $1.02 | $0.96 | $1.06 | $0.902 | 141,906 | 04-10-2019 |
$ | $0.9912 | $1.01 | $1.06 | $0.99 | 117,846 | 04-09-2019 |
$ | $1.09 | $0.99 | $1.13 | $0.943 | 468,356 | 04-08-2019 |
$ | $1.10 | $1.08 | $1.15 | $1.05 | 170,948 | 04-05-2019 |
$ | $1.12 | $1.11 | $1.20 | $1.09 | 126,280 | 04-04-2019 |
$ | $1.16 | $1.13 | $1.23 | $1.01 | 584,690 | 04-03-2019 |
News, Short Squeeze, Breakout and More Instantly...
OncoMed Pharmaceuticals Inc. Company Name:
OMED Stock Symbol:
NASDAQ Market:
OncoMed Pharmaceuticals Inc. Website:
Notice of Preliminary Results THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Mereo...
LONDON, April 18, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces today that stockholders of OncoMed (NASDAQ: OMED) have approved the transactions contemplated by the merger agreement da...
REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declar...